PNPLA3rs738409G/C基因多态性与肝癌易感性关系的Meta分析

目的 探讨PNPLA3基因多态性与肝癌易感性关系。方法 计算机检索数据库，收集有关PNPLA3基因多态性与肝癌病易感性关系病例对照研究，提取纳入文献的相关数据进行Meta分析，以病例组与对照组PNPLA3各种基因模型的比值比（OR）为效应指标，Egger''s检验和Bgger''s检验偏倚。结果 共8篇研究符合纳入标准，累计病例数1266例，对照组3529例。Meta分析表明PNPLA3基因多态性与肝癌病易感性有明显关联性。结论 PNPLA3基因多态性与肝癌病易感性明显关联性［GG vs CC：OR=3.05，95%CI：2.42～3.86；CG vs CC：OR=1.30，95%CI：1.13～1.50；CG/GG vs CC：OR=1.39，95%CI：1.23～1.57；GG vs CG/CC：OR=2.90，95%CI：2.32～3.63］。

Association between PNPLA3 Polymorphism and Hepatocellular Carcinoma Susceptibility: A Meta-analysis

Objective To explore the association between the PNPLA3 polymorphism and Hepatocellular carcinoma susceptibility. Methods Data bases were comprehensively searched to retrace all the related studies on the associations between PNPLA3 polymorphismand hepatocellular carcinoma susceptibility in European population. The pooled odds ratios (ORs) with 95% confidence intervals (95%CIs) of the association between PNPLA3 polymorphism and hepatocellular carcinoma susceptibility were performed in different genetic model comparison. Publication bias was detected by symmetry of funnel plot. Results Eight original studies with a total of 4795 subjects (1266 patients and 3529 controls) were entered the final data combination. The results of Meta-analyses showed that there were no significant associations between PNPLA3 polymorphism and hepatocellular carcinoma susceptibility GG vs CC:OR=3.05,95% CI: 2.424-3.86;CG vs CC:OR=1.30,95 %CI:1.13-1.50;CG/GG vs CC:OR=1.39, 95% CI:1.23-1.57; GG vs CG/CC:OR=2.90, 95% CI: 2.32-3.63]. Conclusion Meta-analysis strongly suggests that there are significant associations between PNPLA3 polymorphism and hepatocellular carcinoma susceptibility.